The Utility of ODM-201 in CRPC
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).
Clinical Pearls
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).
- In phase I and II multinational trials, favorable results have been observed regarding PSA kinetics modulation
- The organic structure of ODM-201 seems to cause the agent to have a much lower penetration through the blood-brain barrier
- The efficacy of ODM-201 is being measured in terms of its impact on radiographic disease, PSA, and the androgen receptor
- ODM-201 has been studied in patients prior to and following chemotherapy, as well as in patients who have and have not received abiraterone
- Additional trials are being planned to analyze safety, efficacy, and tolerability
- ODM-201 will be studied in a large trial of non-metastatic patients
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
